PREDICTION OF ALL-CAUSE MORTALITY AND CARDIOVASCULAR EVENTS IN END STAGE RENAL DISEASE WITH CENTRAL HAEMODYNAMICS: A SYSTEMATIC REVIEW PROTOCOL

3 Bárbara Letícia da Silva Guedes de Moura^{1,2}; Felipe Steinmacher Batista³; Guilherme Luiz Rodrigues

Barbara Leticia da Siva Guedes de Moura-³; Pelipe Steinmacher Batista³; Guinerme Luiz Rodrigues
 Ramajo³; Gustavo Bueno Valente³; João Vitor Scalon Estércio Rizzo³; Tarik Radi Campos Maftoum³; Izabel
 Calbarda Demonshi⁴ Sérvia Saliti Yama da²5 Deséria Tarbina Deserva Channel³5 James Martena

- Galhardo Demarchi⁴; Sérgio Seiji Yamada^{2,5}; Rogério Toshiro Passos Okawa^{2,3,5}; Jorge Juarez Vieira Teixeira
 ^{2,6}.
- 7 <u>blguedes@gmail.com; felipe1810@gmail.com; guilhermeramajo@gmail.com; gbvalente99@gmail.com;</u>
- 8 joaovitorscalon13@gmail.com; tarikmaf@gmail.com; i.g.demarchi@ufsc.br;sergioyamada62@gmail.com;
- 9 rogerokawa@uol.com.br; jjvteixeira@gmail.com
- 10

11 Authors' information:

- 12 1 Graduate Program in Biosciences and Physiopathology (PBF), State University of Maringa,
- 13 Maringá, PR
- 2 Systemic Arterial Hypertension, Arterial Stiffness and Vascular Aging Research Group(GPHARV/UEM)
- 16 3 Systemic Arterial Hypertension Academic League, Regional University Hospital, State
- 17 University of Maringa, PR, BR.
- 18 4 Clinical Analysis Department, Federal University of Santa Catarina (UFSC), SC
- 19 5 Medical Department, State University of Maringa, Maringá, PR
- 20 6 Clinical Analysis and Biomedicine Department, State University of Maringa, PR
- 21

22 Institutional addresses:

- 23 ^{1, 2, 3, 5, 6} State University of Maringá: Universidade Estadual de Maringá, Maringá PR/BR. Av.
- 24 Colombo, 5790, Jd Universitario. CEP: 87.020-900\CCS. + 55 44 3011 4890.
- ⁴Federal University of Santa Catarina (UFSC): Universidade Federal de Santa Catarina CCS -
- 26 Departamento de Análises Clínicas Campus Universitário Trindade. CEP: 88.040-970 -
- 27 Florianópolis SC. Fone: +55 48 3721 4159.

28 Corresponding author:

- 29 Barbara Leticia da Silva Guedes de Moura
- Av. Colombo, 5790 Zona 7, Maringá PR, 87020-900. Bloco I-90. sala 8. Prof. Jorge Teixeira.
- 31 <u>www.uem.br</u>
- 32 5544999281401
- 33 <u>blsguedes@gmail.com</u>

34

35 ABSTRACT

36

37 Background: Given the high rates of adverse events in End-stage renal disease (ESRD) patients 38 and as the applications of central haemodynamics (central blood pressure, augmentation index, 39 pulse wave velocity) in dialysis patients have not been fully clarified, we, therefore, will perform 40 a systematic review of central haemodynamics as a predictor of total and cardiovascular 41 mortality and morbidity in the ESRD population. Methods: This protocol is reported according 42 to the PRISMA-P guideline. The databases PubMed, EMBASE, LILACS, Web of Science, and 43 Google Scholar system will be searched and double screening for prospective studies that 44 assessed the prospective association of central haemodynamics parameters with at least one of 45 the pre-specified outcomes in ESRD patients. Discrepancies will be resolved through consensus. 46 A modified version of the Newcastle-Ottawa Quality Assessment Scale of cohort studies will be 47 used. We intend to use the random-effects model, considering at least moderate heterogeneity 48 between studies. If data allow, we will perform a sensitivity analysis to explore potential sources 49 of between-study heterogeneity. Discussion: This systematic review will summarize current 50 evidence about central haemodynamics measures in the ESRD patients and clarify the 51 incremental prognostic value of this diagnostic tool in these patients. Therefore, this systematic 52 review will also be displayed important knowledge gaps in the current literature regarding the 53 possible utility of central haemodynamics indices in ESRD patients.

54 Systematic review registration

55 This systematic review protocol was submitted to the PROSPERO international registry of 56 systematic reviews (Registration number: CRD42022260824).

57 Keywords

58 End-Stage renal disease; prognosis; central blood pressure; augmentation index; pulse wave

59 velocity.

60 Strengths and limitations of this study

→ The PROSPERO registry helps to promote and maintain transparency in the process and to
 assist in minimizing the risk of bias. Four databases and one additional grey literature source
 helps ensure more complete coverage of the topic. All the review phases will be peer-reviewed
 and will be validated by methodological and clinical experts.

45 → Central (aortic, carotid) pressures are pathophysiologically more relevant than peripheral
 b) pressures for the pathogenesis of cardiovascular (CV) disease. There is a cumulative increase in
 b) CVD during the transition from CKD to ESRD: as patients initiate dialysis, there are significant
 c) changes in blood pressure, volume status, and circulating solutes, all of which may contribute to
 c) increased risk of CVD. Studies did not further analyze the ability of central pressures and indices
 c) to predict future events in separated stages of CKD, especially in End-stage renal disease patients
 c) patients.

→ This study has limitations. Because heterogeneity is quite common in these systematic reviews,
 there may be limited scope for meta-analysis. Possibly, the spectrum of patients in different
 research sites is the main factor, in most cases, but heterogeneity in associations between studies
 may be difficult to explain.

→This systematic review will evaluate the evidence related to the Central Haemodynamics
 (central blood pressure, augmentation index, pulse wave velocity) incremental prognostic value
 in ESRD patients, which may lower morbidity and mortality and influence its use as a prognostic

79 marker for ESRD patients.

80 Background

End-stage renal disease (ESRD) is a rapidly increasing global health and health care burden. The number of people receiving renal replacement therapy (RRT) exceeds 2.5 million and is projected to double to 5.4 million by 2030 (1). Data from the US Renal Data System (USRDS) reported that among CKD patients who die, 91% have a diagnosis of cardiovascular disease (CVD) overall, 57% have a diagnosis of coronary (CAD), and 63% have a diagnosis of Heart Failure (HF).

Although classical Framingham risk factors remain important, there is increasing evidence to support renal-specific and dialytic disturbances increases the CV risk in this population, such as sodium/fluid balance, hyperuricemia, inflammation, vascular calcification, and abnormal bone mineral metabolism, and these complex interaction results in a high prevalence of abnormalities of cardiac structure and function in patients with ESRD (2,3).

91 Central (aortic, carotid) pressures are pathophysiologically more relevant than peripheral 92 pressures for the pathogenesis of cardiovascular (CV) disease. Central haemodynamics 93 (central/aortic blood pressure, augmentation index, pulse wave velocity) can now be reliably 94 assessed non-invasively with a number of relatively inexpensive devices (4). While several 95 studies have shown the ability of central pressures and indices to predict future events, findings 96 have not always been consistent in the ESRD patients (5). Studies did not further analyze central 97 haemodynamics in different stages of CKD, especially in ESRD patients. There is a cumulative 98 increase in CVD during the transition from CKD to ESRD: as patients initiate dialysis, there are 99 significant changes in blood pressure, volume status, and circulating solutes, all of which may 100 contribute to increased risk of CVD (3,6,7).

Given the high rates of adverse events in dialysis patients and as the applications of central haemodynamics in dialysis patients have not been fully clarified, we, therefore, will perform a systematic review of central haemodynamics as a predictor of total and cardiovascular mortality and morbidity in the ESRD population.

105 Methods/Design

106 This protocol is reported according to the Preferred Reporting Items for Systematic 107 Reviews and Meta-Analyses Protocols (PRISMA-P) (8) and the corresponding checklist used 108 (Supplementary file 1). This includes details of inclusion and exclusion criteria, a data extraction 109 tool, and analytical methods. This systematic review protocol was submitted to the PROSPERO 110 international registry of systematic reviews (Registration number: CRD42022260824).

111 Review question

112 Is the Central Haemodynamics (central blood pressure, augmentation index, pulse wave 113 velocity) a better prognostic marker than peripheral measures (brachial blood pressure/ no 114 control) in the End Stage Renal Disease?

- 115 P: End-stage renal disease patients
- 116 E: Central Haemodynamics (Central blood pressure, Augmentation Index and/or Pulse Wave 117 Velocity)
- 118 C: Peripheral (brachial) blood pressure / no restriction
- 119 O: All-cause mortality, cardiovascular events
- 120 S: Prospective studies
- 121 Searches

MEDLINE (using the PubMed interface), Web of Science, LILACS (Latin American and Caribbean Literature in Health Sciences) and Google Scholar (grey literature) databases and reference lists of eligible studies will be searched for publications until the search date. The Search strategy were determined independently by three authors (BLSG, RTPO and JJVT). The search will be

were determined independently by three authors (BLSG, RTPO and JJVT). The search will be limited to original research reports in peer-reviewed journals with no language or publication date restriction.

- 127 uale restriction
- 128 Search strategy

The search strategy will be developed first for the MEDLINE database and the effectiveness will be tested and refined accordingly, using the keywords 'Central Aortic Blood Pressure, 'Pulse Wave Analysis', 'Vascular stiffness', 'chronic kidney disease', 'hemodialysis'. A detailed draft for the search strategy to be used is detailed in Supplementary file 2.

133 Eligibility criteria

All longitudinal studies that assessed the prospective association of one or more index of central haemodynamics (central blood pressure - cBP, Augmentation Index - Aix, or Pulse Wave Velocity - PWV) with: (a) at least one of the pre-specified outcomes in ESRD (>18 years) population and (b) in accordance with ethical standards, will be included and (c) Patients data with CKD in different stages, (not only ESRD or which one that not reported the results separately according to the CKD stage) and (d) Abstracts, reviews, conference proceedings or letters to the editor will be excluded.

Search results from each database will be combined and duplicates will be removed before the screening. References will be aggregated into a reference manager tool (EndNote Web) (9). Additional papers will be identified by searching the reference lists of relevant articles and their citation metrics.

- A draft for the Eligibility and Data Extraction Form to be used is detailed in Supplementary file3.
- 147 Outcomes and Measures of effect

148 The primary outcome will be all-cause mortality whereas secondary outcomes will be a 149 composite cardiovascular (endpoint includes: CV mortality, Coronary Heart Disease (CHD) 150 events (Myocardial infarction (MI), unstable angina, angina/ischemia requiring emergent hospitalization or revascularization), Heart Failure (HF) hospitalization, new onset Atrial 151 152 Fibrillation (AF), life threatening arrhythmia, recorded automatic implantable cardioverter 153 defibrillator (AICD) shocks, stroke, transit ischemic attack, peripheral arterial disease (PAD) with 154 arterial revascularization procedure). Tertiary outcomes will be any individual secondary 155 endpoint not included in the composite cardiovascular.

- We will provide a narrative synthesis of the findings from the included studies. We will provide summaries of intervention effects for each study by calculating risk ratios (for dichotomous outcomes) or standardized mean differences (for continuous outcomes) from the data presented in the published studies or obtained from study authors.
- 160 Study reviews and appraisals

161 Initial title and abstract screening will be performed using Rayyan software (10) and full texts of 162 selected articles will be retrieved and double screened for eligibility and data extraction by six 163 researchers working independently (BLSGM, FSB, GLRR, GBV, JVSER, TRCM). Discrepancies will 164 be resolved through consensus or the opinion of a third review author (JJVT or RTPO) will be 165 sought. For multiple study publications from the same patient cohort, we will choose the study 166 with the largest number of cases, or which one that reported the results separately according 167 to the CKD stage, once there are many studies whose results of patients with early-to-moderate 168 CKD stage are reported together with ESRD patients, which makes it impossible to correctly 169 analyze these subgroups. For studies that presented different outcomes, we will be extracted 170 outcomes from both publications.

171 Reasons for study exclusion will be documented. Data extraction will be validated by 172 methodological and clinical experts (IGD, JJVT and RTPO, SSY, respectively). Also, information 173 reported in the grey literature will be sought. We will report our search terms as an appendix to 174 published studies.

175 Data extraction

176 We will extract the following data: (a) citation details (title, type, and year of publication); (b) 177 study details (name, region, and design of the study, sample size); (c) participant details 178 including demographics (age, sex, ethnicity, and follow-up duration), clinical (hypertension, 179 diabetes mellitus-DM, dyslipidemia, smoking status, and known CVD), and laboratory variables; 180 (d) exposure details (hardware and the software used for the measures acquisition and analysis); 181 (e) details of outcomes, including how these were ascertained; (f) statistical methods used, as 182 well as statistics related to the association of interest, and (g) information related to adjustment 183 for potential confounders.

- 184 If samples are reported at multiple time points within a study, then each one will be considered 185 individually. If these data are not available, we will extract the association measures that were 186 used. The relevant authors will not be contacted for further information.
- 187 Quality assessment, data synthesis, and exploration of heterogeneity
- 188 Risk of bias (quality) assessment

- 189 A modified version of the Newcastle-Ottawa Quality Assessment Scale of cohort studies (NOS)
- 190 (11) will be used to assess the quality of included papers (Supplementary file 4). Studies will not
- 191 be excluded from the main meta-analysis based on the risk of bias.
- 192 Strategy for data synthesis

193 Statistical analyses will be performed using Review Manager 5.4 software. This information will 194 be summarized graphically in the final review document. The degree of heterogeneity will be 195 assessed using the Higgins Thompson I² test (12) and Cochran's Q test (13). If the included 196 studies are sufficiently homogeneous, a quantitative synthesis using random-effect meta-197 analysis will be used to pool the results of the association of interest. For presenting the results, 198 we will likely use the HR (95%CI) as an effect estimate and will present the data graphically in 199 forest plots. If data allow, we will perform a sensitivity analysis to explore potential sources of 200 between-study heterogeneity: (a) study quality, (b) variation in exposure measurement, and (c) 201 variation in CV outcomes definition. Possible publication bias will be assessed using a Funnel 202 plot (14). We will assess evidence of publication bias using Egger's weighted regression method 203 for continuous outcomes and Begg's rank correlation test for dichotomous outcomes.

204 Discussion

This systematic review will summarize current evidence about the incremental prognostic value of central haemodynamics measures in the ESRD patients. Studies reported associations between central haemodynamics measures and all-cause mortality and cardiovascular events, but, is not fully understood the potential prognostic value of this diagnostic tool in ESRD patients. Therefore, this systematic review will also be displayed important knowledge gaps in the current literature regarding the possible utility of central haemodynamics indices in ESRD patients.

212 Though hemodialysis (HD) should theoretically improve cardiovascular function by correcting 213 fluid overload and small molecule accumulation, cardiovascular mortality continues to be 214 disproportionately high in the HD population (1,2). The impact of renal replacement therapy 215 (RRT) on cardiovascular function and injury is not well understood and may inadvertently be 216 contributing to the accelerated development of type 4 cardiorenal syndrome (CRS): CKD leading 217 to an impairment of cardiac function. The unique physiology of cardiovascular abnormalities in 218 dialysis patients remains poorly understood and several more recently recognized factors, 219 including altered lipid metabolism and accumulation of gut microbiota-derived uremic toxins, 220 also affect cardiovascular function in the context of renal failure (15).

A crucial remaining question is whether central BP offers significant improvement in cardiovascular risk assessment and stratification compared with brachial (peripheral) BP. Several studies showed superiority of central compared with brachial BP; yet these findings have not always been consistent.

This systematic review will provide essential data regarding central haemodynamics as prognostic indicators of mortality and CV events in End-stage renal disease patients. The clinical implications of this work relate to the current status of diagnosis and treatment of heart disease in patients receiving dialysis.

229 Availability of data and materials

The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.

232 List of Abbreviations

233 Aix: Augmentation Index

- 234 AF: Atrial fibrillation
- 235 AICD: Automatic implantable cardioverter defibrillator
- 236 BP: blood pressure
- 237 CHD: Coronary heart disease
- 238 CKD: chronic kidney disease
- 239 CRS: Cardiorenal syndrome
- 240 CV: Cardiovascular
- 241 CVD: Cardiovascular disease
- 242 DM: Diabetes mellitus
- 243 ESRD: End-stage renal disease
- 244 HD: Hemodialysis
- 245 HF: Heart failure
- 246 LILACS: Latin American and Caribbean Literature in Health Sciences
- 247 MI: Myocardial infarction
- 248 NOS: Newcastle-Ottawa Quality Assessment Scale of cohort studies
- 249 PRISMA-P: Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols
- 250 PROSPERO: International registry of systematic reviews
- 251 PP: Pulse pressure
- 252 PWV: Pulse wave velocity
- 253 RRT: Renal replacement therapy
- 254 UC: Uremic cardiomyopathy

255 **REFERENCES**

USRDS ADR. Epidemiology of kidney disease in the United States. National Institutes of
 Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD. 2019
 november. Available from: https://www.usrds.org/annual-data-report/

- 2. Bansal N. Evolution of Cardiovascular Disease During the Transition to End-Stage Renal
 Disease. Semin Nephrol. 2017 Mar;37(2):120-131. eng. doi:10.1016/j.semnephrol.2016.12.002.
 Cited in: Pubmed; PMID 28410646.
- 262 3. Ibrahim MK, Kamal OMM, Hassan MS, Khalifa MMM. Interdialytic Weight Gain and Its
- 263 Relation to Outcome among Patients on Maintenance Hemodialysis. QJM: An International
- 264 Journal of Medicine. 2020 2020-03-01;113(Supplement_1). doi:10.1093/qjmed/hcaa052.020.
- 265 4. Battistoni A, Michielon A, Marino G, Savoia C. Vascular Aging and Central Aortic Blood
- 266 Pressure: From Pathophysiology to Treatment. High Blood Press Cardiovasc Prev. 2020
- 267 Aug;27(4):299-308. doi: 10.1007/s40292-020-00395-w. Epub 2020 Jun 22. PMID: 32572706.

5. Sabovic M, Safar ME, Blacher J. Is there any additional prognostic value of central blood
pressure wave forms beyond peripheral blood pressure? Curr Pharm Des. 2009;15(3):254-66.

- 270 doi: 10.2174/138161209787354249. PMID: 19149615.
- 6. Briet M, Boutouyrie P, Laurent S, London GM. Arterial stiffness and pulse pressure in CKD
 and ESRD. Kidney Int. 2012 Aug;82(4):388-400. doi: 10.1038/ki.2012.131. PMID: 22534962.
- 273 7. Protogerou AD, Papaioannou TG, Lekakis JP, Blacher J, Safar ME. The effect of
- 274 antihypertensive drugs on central blood pressure beyond peripheral blood pressure. Part I:
- 275 (Patho)-physiology, rationale and perspective on pulse pressure amplification. Curr Pharm Des.
- 276 2009;15(3):267-71. doi: 10.2174/138161209787354267. PMID: 19149617.
- 277 8. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA.
- 278 Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P)
- 279 2015 statement. Syst Rev. 2015; 4(1):1. doi: 10.1186/2046-4053-4-1.
- 9. ENDNOTE WEB McKinney, A. EndNote Web: Web-Based Bibliographic Management. Journal
 of electronic resources in medical libraries, 2013 10(4), 185-192.
- 10. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for
 systematic reviews. Systematic reviews, 2016. 5(1), 210.
- 11. Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. Newcastle-Ottawa
 quality assessment scale cohort studies. 2014. 2015-11-19]. Available on: http://www.
 ohri.ca/programs/clinical epidemiology/oxford. asp.
- 12. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ
 2003;327:557–60. 45. Higgins JP, Thompson SG. Quantifying heterogeneity in a metaanalysis.
 Stat Med 2002;21:1539–58.
- 13. Cochran WG. The comparison of percentages in matched samples. Biometrika, 1950.
 37(3/4), 256-266.
- 14. Sterne, JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, Tetzlaff J. Recommendations
 for examining and interpreting funnel plot asymmetry in meta-analyses of randomised
 controlled trials. BMJ, 2011 343.
- 15. Ahmadmehrabi S, Wilson Tang WH. Hemodialysis-induced cardiovascular disease. Seminars
 in Dialysis. 2018; 31:258–267.
- 297 **DECLARATIONS**
- 298 <u>Ethics approval and consent to participate:</u> Not applicable.
- 299 <u>Consent for publication:</u> Not applicable.
- Availability of data and materials: All data generated or analyzed during this study are included
 in this published article [and its supplementary information files].
- 302 <u>Competing interests:</u> The authors declare that they have no competing interests.
- 303 <u>Funding:</u> None.
- 304 <u>Authors' contributions:</u> BLSGM has prepared this manuscript with clinical and methodological
- 305 support from RTPO and JJVT, respectively. This manuscript has been reviewed by FSB, GLRR,
- 306 GBV, JVSER, TRCM, IGD, SSY, RTPO and JJVT and edited by IGD, SSY, RTPO and JJVT. BLSGM is

- 307 the corresponding author and has registered the protocol with the PROSPERO database. All
- 308 authors agreed to be accountable for all aspects of this work and approved the final submission.

309 Supplementary information

Supplementary file 1: PRISMA-P Checklist.	<u>Supplementary file 3:</u> Eligibility Form / Data Extraction Form.
Supplementary file 2: Draft Search strategy.	Supplementary file 4: Modified NOS Risk of Bias assessment.

310